-DOCSTART- -X- O
Human -X- _ O
parainfluenza -X- _ O
virus -X- _ O
type -X- _ O
3 -X- _ O
( -X- _ O
HPIV3 -X- _ O
) -X- _ O
is -X- _ O
an -X- _ O
important -X- _ O
cause -X- _ O
of -X- _ O
lower -X- _ O
respiratory -X- _ O
tract -X- _ O
illness -X- _ O
in -X- _ O
children -X- _ O
, -X- _ O
yet -X- _ O
a -X- _ O
licensed -X- _ O
vaccine -X- _ O
or -X- _ O
antiviral -X- _ O
drug -X- _ O
is -X- _ O
not -X- _ O
available. -X- _ O
We -X- _ O
evaluated -X- _ O
the -X- _ O
safety -X- _ O
, -X- _ O
tolerability -X- _ O
, -X- _ O
infectivity -X- _ O
, -X- _ O
and -X- _ O
immunogenicity -X- _ O
of -X- _ O
two -X- _ O
intranasal -X- _ O
, -X- _ O
live-attenuated -X- _ B-Intervention
HPIV3 -X- _ I-Intervention
vaccines -X- _ I-Intervention
, -X- _ O
designated -X- _ O
rHPIV3-N -X- _ O
( -X- _ O
B -X- _ O
) -X- _ O
and -X- _ O
rB -X- _ O
/ -X- _ O
HPIV3 -X- _ O
, -X- _ O
that -X- _ O
were -X- _ O
cDNA-derived -X- _ O
chimeras -X- _ O
of -X- _ O
HPIV3 -X- _ O
and -X- _ O
bovine -X- _ O
PIV3 -X- _ O
( -X- _ O
BPIV3 -X- _ O
) -X- _ O
. -X- _ O
These -X- _ O
were -X- _ O
evaluated -X- _ O
in -X- _ O
adults -X- _ B-Patient
, -X- _ O
HPIV3 -X- _ B-Patient
seropositive -X- _ I-Patient
children -X- _ I-Patient
, -X- _ O
and -X- _ O
HPIV3 -X- _ B-Patient
seronegative -X- _ I-Patient
children. -X- _ I-Patient
A -X- _ O
total -X- _ O
of -X- _ O
112 -X- _ B-Patient
subjects -X- _ I-Patient
participated -X- _ O
in -X- _ O
these -X- _ O
studies. -X- _ O
Both -X- _ B-Outcome
rB -X- _ I-Outcome
/ -X- _ I-Outcome
HPIV3 -X- _ I-Outcome
and -X- _ I-Outcome
rHPIV3-N -X- _ I-Outcome
( -X- _ I-Outcome
B -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
highly -X- _ I-Outcome
restricted -X- _ I-Outcome
in -X- _ I-Outcome
replication -X- _ I-Outcome
in -X- _ I-Outcome
adults -X- _ I-Outcome
and -X- _ I-Outcome
seropositive -X- _ I-Outcome
children -X- _ I-Outcome
but -X- _ I-Outcome
readily -X- _ I-Outcome
infected -X- _ I-Outcome
seronegative -X- _ I-Outcome
children -X- _ I-Outcome
, -X- _ I-Outcome
who -X- _ I-Outcome
shed -X- _ I-Outcome
mean -X- _ I-Outcome
peak -X- _ I-Outcome
virus -X- _ I-Outcome
titers -X- _ I-Outcome
of -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
2.8 -X- _ I-Outcome
) -X- _ I-Outcome
vs. -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
3.7 -X- _ I-Outcome
) -X- _ I-Outcome
pfu -X- _ I-Outcome
/ -X- _ I-Outcome
mL -X- _ I-Outcome
, -X- _ I-Outcome
respectively. -X- _ I-Outcome
Although -X- _ I-Outcome
rB -X- _ I-Outcome
/ -X- _ I-Outcome
HPIV3 -X- _ I-Outcome
was -X- _ I-Outcome
more -X- _ I-Outcome
restricted -X- _ I-Outcome
in -X- _ I-Outcome
replication -X- _ I-Outcome
in -X- _ I-Outcome
seronegative -X- _ I-Outcome
children -X- _ I-Outcome
than -X- _ I-Outcome
rHPIV3-N -X- _ I-Outcome
( -X- _ I-Outcome
B -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
it -X- _ I-Outcome
induced -X- _ I-Outcome
significantly -X- _ I-Outcome
higher -X- _ I-Outcome
titers -X- _ I-Outcome
of -X- _ I-Outcome
hemagglutination -X- _ I-Outcome
inhibition -X- _ I-Outcome
( -X- _ I-Outcome
HAI -X- _ I-Outcome
) -X- _ I-Outcome
antibodies -X- _ I-Outcome
against -X- _ I-Outcome
HPIV3. -X- _ I-Outcome
Taken -X- _ O
together -X- _ O
, -X- _ O
these -X- _ O
data -X- _ O
suggest -X- _ O
that -X- _ O
the -X- _ O
rB -X- _ O
/ -X- _ O
HPIV3 -X- _ O
vaccine -X- _ O
is -X- _ O
the -X- _ O
preferred -X- _ O
candidate -X- _ O
for -X- _ O
further -X- _ O
clinical -X- _ O
development -X- _ O
. -X- _ O

